Hepatic Effects, Potential Drug-Induced Liver Injury, and Other Liver Safety Considerations of Chimeric Antigen Receptor T-Cell (CAR-T) Therapy in the New Era of Expanding Non-oncology Indications: Literature Review and Expert Consensus

• Anna FettiplaceAstraZeneca (United Kingdom)
• Arie RegevEli Lilly (United States)
• Alexandre Kiazand
• U. Heinzel-PleinesBayer (Germany)
• Mahnoush BahjatAstraZeneca (United Kingdom)
• Anju Garg
• Luciana Kikuchi
• Hewei LiJohnson & Johnson (United States)
• Ali HamidiAmgen (United States)
• David AlpersWashington University in St. Louis
• Hans Ludger TillmannEast Carolina University
• Dominique G. LarreyHôpital Saint Eloi
• Adrian M. Di BisceglieSaint Louis University
• James H. LewisGeorgetown University